CWBR News and Press, CohBar Inc. From 08/15/22

IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitoch...

MENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...

MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...

MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases,...

CohBar Inc. (CWBR) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets ...

CohBar press release (NASDAQ:CWBR): Q1 GAAP EPS of -$0.04 in-line. The company had cash and investments of $23.5 million as of March 31, 2022. For further details see: CohBar GAAP EPS of -$0.04 in-line

MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases,...

ADMP, ALBO, ANY, AREC, ASTS, AXDX, CCSI, OTCQX:CWBHF, CWBR, CYRN, DAC, DADA, DNA, EGLX, FTK, FUV, GAN, GLBE, GNLN, HYRE, INPX, IONQ, IPWR, ISUN, IZEA, KBNT, KULR, MARK, MVST, OTCQB:NEXCF, NU, OTCQX:PLNHF, PPSI, PYR, QIPT, REED, REKR, RGTI, RKLB, RMTI, SHLS, OTCQX:SHWZ, SLGG, SNDL, SPI, SPRO, ...

CohBar (NASDAQ:CWBR) Q1 consensus EPS estimate is -$0.07 and consensus revenue estimate is $0M. CWBR is scheduled to announce Q1 earnings results on Friday, May 13, after market close. For further details see: CohBar Q1 2022 Earnings Preview